Latest Neurotrope Inc. (NTRP) Headlines
Neurotrope, Inc., Hires Three Experienced Senior Pharmaceutical Executives - A Chief Medical Officer and Heads of Commercial Operations and Regulatory Affairs
PR Newswire - Tue Jan 28, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President, Regulatory Affairs. All three new executives will report to Dr. James New, the Company's President and Chief Executive Officer.
Neurotrope, Inc., to Present at Noble Financial Tenth Annual Equity Conference in Sandpiper Bay, Florida
PR Newswire - Tue Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that Dr. James New, the Company's President and Chief Executive Officer, will present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 11:00AM Eastern Time on Tuesday, January 21, 2014 at the Club Med Resort in Sandpiper Bay, Florida.
Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
PR Newswire - Mon Jan 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that the Company will present at the Biotech Showcase 2014 conference 8:00AM Pacific Time on Monday, January 13, 2014 at the Parc 55 Wyndham Hotel, Union Square in San Francisco, California.
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
PR Newswire - Mon Dec 16, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that James Gottlieb has been appointed to the Company's Board of Directors. Mr. Gottlieb has extensive senior level experience in a broad range of positions in Washington, D.C., in the U.S. House and Senate, and in the private and non-profit sectors. During his time in Washington, Mr. Gottlieb directed significant congressional policy and oversight matters regarding the Food and Drug Administration ("FDA") and health-related aspects of the Veterans Administration, the largest civilian health provider in the nation.
Neurotrope, Inc., Appoints Paul E. Freiman to the Company's Board of Directors
PR Newswire - Tue Oct 22, 7:30AM CDT
Neurotrope, Inc. (OTCQB:NTRP) (the "Company") announced today that Paul E. Freiman has been appointed to the Company's Board of Directors. Mr. Freiman has extensive pharmaceutical and biotechnology industry operating experience as a board member and Chief Executive Officer of private and publicly traded companies and is a pharmacist.
Neurotrope, Inc., Announces Dr. Larry D. Altstiel, M.D., Ph.D. Appointed to the Company's Scientific Advisory Board
PR Newswire - Tue Oct 15, 7:30AM CDT
Neurotrope, Inc. (OTCQB:NTRP) (the "Company") announced today that Dr. Larry D. Altstiel, M.D., Ph.D. has been appointed to the Company's Scientific Advisory Board. Dr. Altstiel is an expert in several neurodegenerative disease states with respect to their potential causes and treatments. He has extensive clinical and operational experience in pharmaceutical development and has published many related articles and abstracts in his field of study.
Neurotrope, Inc. Announces Closing of Additional $1.08 Million of its Private Offering
PR Newswire - Wed Oct 09, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it completed a closing of the sale of 1,080,000 shares of its Series A convertible preferred stock in a private offering to accredited investors, at a price of $1.00 per share, resulting in gross proceeds to Neurotrope of $1,080,000 (before deducting commissions and expenses of the offering). Neurotrope had previously sold 21,920,000 shares of its Series A convertible preferred stock in three prior closings of this private placement in February, May and August 2013, at the same purchase price per share, for aggregate gross proceeds of $21,920,000 (before deducting commissions and expenses of the offering). The total gross amount raised by Neurotrope in its Series A convertible preferred offering has been $23,000,000.
Neurotrope, Inc., Announces Hiring Robert Weinstein As Executive Vice President and Chief Financial Officer
PR Newswire - Mon Oct 07, 7:30AM CDT
Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB: NTRP), a Nevada corporation (the "Company"), announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer. Mr. Weinstein had been the acting Chief Financial Officer, as a consultant, since May 2013 and was instrumental in executing the Company's private financings and reverse merger, which both closed in August 2013.
Neurotrope, Inc., Announces New Trading Symbol
PR Newswire - Tue Sep 10, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP), a Nevada corporation (the "Company"), announced that effective today the trading symbol for its common stock has changed from "BLFLD" to "NTRP," reflecting the Company's name change from BlueFlash Communications, Inc., to Neurotrope Inc., in connection with its reverse merger with Neurotrope BioScience, Inc., which was completed on August 23, 2013, as previously announced. Shares of the Company's common stock are quoted in the OTCQB marketplace.
Neurotrope, Inc., Hires Three Experienced Senior Pharmaceutical Executives - A Chief Medical Officer and Heads of Commercial Operations and Regulatory Affairs
PR Newswire - Tue Jan 28, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President, Regulatory Affairs. All three new executives will report to Dr. James New, the Company's President and Chief Executive Officer.
Neurotrope, Inc., to Present at Noble Financial Tenth Annual Equity Conference in Sandpiper Bay, Florida
PR Newswire - Tue Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that Dr. James New, the Company's President and Chief Executive Officer, will present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 11:00AM Eastern Time on Tuesday, January 21, 2014 at the Club Med Resort in Sandpiper Bay, Florida.
Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
PR Newswire - Mon Jan 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that the Company will present at the Biotech Showcase 2014 conference 8:00AM Pacific Time on Monday, January 13, 2014 at the Parc 55 Wyndham Hotel, Union Square in San Francisco, California.
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
PR Newswire - Mon Dec 16, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that James Gottlieb has been appointed to the Company's Board of Directors. Mr. Gottlieb has extensive senior level experience in a broad range of positions in Washington, D.C., in the U.S. House and Senate, and in the private and non-profit sectors. During his time in Washington, Mr. Gottlieb directed significant congressional policy and oversight matters regarding the Food and Drug Administration ("FDA") and health-related aspects of the Veterans Administration, the largest civilian health provider in the nation.
Neurotrope, Inc., Appoints Paul E. Freiman to the Company's Board of Directors
PR Newswire - Tue Oct 22, 7:30AM CDT
Neurotrope, Inc. (OTCQB:NTRP) (the "Company") announced today that Paul E. Freiman has been appointed to the Company's Board of Directors. Mr. Freiman has extensive pharmaceutical and biotechnology industry operating experience as a board member and Chief Executive Officer of private and publicly traded companies and is a pharmacist.
Neurotrope, Inc., Announces Dr. Larry D. Altstiel, M.D., Ph.D. Appointed to the Company's Scientific Advisory Board
PR Newswire - Tue Oct 15, 7:30AM CDT
Neurotrope, Inc. (OTCQB:NTRP) (the "Company") announced today that Dr. Larry D. Altstiel, M.D., Ph.D. has been appointed to the Company's Scientific Advisory Board. Dr. Altstiel is an expert in several neurodegenerative disease states with respect to their potential causes and treatments. He has extensive clinical and operational experience in pharmaceutical development and has published many related articles and abstracts in his field of study.
Neurotrope, Inc. Announces Closing of Additional $1.08 Million of its Private Offering
PR Newswire - Wed Oct 09, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it completed a closing of the sale of 1,080,000 shares of its Series A convertible preferred stock in a private offering to accredited investors, at a price of $1.00 per share, resulting in gross proceeds to Neurotrope of $1,080,000 (before deducting commissions and expenses of the offering). Neurotrope had previously sold 21,920,000 shares of its Series A convertible preferred stock in three prior closings of this private placement in February, May and August 2013, at the same purchase price per share, for aggregate gross proceeds of $21,920,000 (before deducting commissions and expenses of the offering). The total gross amount raised by Neurotrope in its Series A convertible preferred offering has been $23,000,000.
Neurotrope, Inc., Announces Hiring Robert Weinstein As Executive Vice President and Chief Financial Officer
PR Newswire - Mon Oct 07, 7:30AM CDT
Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB: NTRP), a Nevada corporation (the "Company"), announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer. Mr. Weinstein had been the acting Chief Financial Officer, as a consultant, since May 2013 and was instrumental in executing the Company's private financings and reverse merger, which both closed in August 2013.
Neurotrope, Inc., Announces New Trading Symbol
PR Newswire - Tue Sep 10, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP), a Nevada corporation (the "Company"), announced that effective today the trading symbol for its common stock has changed from "BLFLD" to "NTRP," reflecting the Company's name change from BlueFlash Communications, Inc., to Neurotrope Inc., in connection with its reverse merger with Neurotrope BioScience, Inc., which was completed on August 23, 2013, as previously announced. Shares of the Company's common stock are quoted in the OTCQB marketplace.
